Galen Growth has just released a new report on the HealthTech Investment Landscape in Asia.
Insights include:
Asia Pac HealthTech ecosystem momentum continues despite geopolitical and domestic headwinds to close at US$5B invested, across 340 deals, well ahead of our forecast last October;
Early stage and Series A deal activity shrinks yet further, whereas total Series B deal value share continues to grow, raising questions on the forward quality of deals by Growth stage investors and the likely impact on Seed stage ventures;
China slows with dollars to VC-backed ventures shrinking. Are investors being spooked by geo-political and domestic economy headwinds?
India’s momentum, after a significant dip in value and volume in Q1, accelerated to make 2019 a record breaking year;
SE Asia investment also broke all previous records and doubled in 2019, reflecting its growing ecosystem maturity;
New in our annual report, we spotlight both the Japan and South Korea ecosystems as these have grown substantially.
